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OBJECTIVE—To evaluate the potential therapeutic effect of
recombinant human tumor necrosis factor (TNF)-related apop-
tosis-inducing ligand (TRAIL) treatment in a model of type 1
diabetes.
RESEARCH DESIGN AND METHODS—Recombinant TRAIL
was added in vitro to primary human and mouse peripheral blood
mononuclear cells (PBMCs) and isolated human islets to evalu-
ate the expression of the immunoregulatory gene SOCS1. Diabe-
tes was induced by ﬁve consecutive daily injections of low-
concentration (50 mg/kg) streptozotocin (STZ) in C57 black mice
(n  24). A group of these mice (n  12) was co-injected with
recombinant TRAIL (20 g/day) for 5 days, and the diabetic
status (glycemia and body weight) was followed over time. After
6 weeks, circulating levels of insulin, TNF-, and osteoprotegerin
(OPG) were measured, and animals were killed to perform the
histological analysis of the pancreas.
RESULTS—The in vitro exposure of both PBMCs and human
islets to recombinant TRAIL signiﬁcantly upregulated the expres-
sion of SOCS1. With respect to STZ-treated animals, mice co-
injected with STZTRAIL were characterized by 1) lower levels
of hyperglycemia, 2) higher levels of body weight and insuline-
mia, 3) a partial preservation of pancreatic islets with normal
morphology, and 4) a lower expression of both systemic (TNF-
and OPG) and pancreatic (vascular cell adhesion molecule
[VCAM]-1) inﬂammatory markers.
CONCLUSIONS—Overall, these data demonstrate that the ad-
ministration of recombinant TRAIL ameliorates the severity of
STZ-induced type 1 diabetes, and this effect was accompanied by
the upregulation of SOCS1 expression. Diabetes 59:1261–
1265, 2010
W
hile a large amount of data are available
about tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL) as an an-
ticancer agent (1), some studies have sug-
gested a potential role of endogenous TRAIL in type 1
diabetes (2–4). When TRAIL function was blocked
through the systemic administration of a soluble TRAIL
receptor into NOD mice, the onset of diabetes was signif-
icantly increased, and the degree of autoimmune inﬂam-
mation was augmented in pancreatic Langerhans islets as
a result of TRAIL blockage (2,3). In addition, normal
primary islet cells are resistant to TRAIL-induced cytotox-
icity (5,6), and adenovirus-mediated TRAIL gene delivery
into pancreatic islets resulted in prolonged normoglyce-
mia in streptozotocin (STZ)-induced diabetic rats com-
pared with animals grafted with mock-infected islets (6).
Our present study aimed to investigate the effects of
recombinant TRAIL on the expression of SOCS1, a gene
known to modulate the sensitivity of both immune cells
and pancreatic -cells to key inﬂammatory cytokines
elevated in diabetes (7–10), in peripheral blood mononu-
clear cells (PBMCs), and puriﬁed human pancreatic islets.
Moreover, we have analyzed the in vivo effect of treatment
with recombinant TRAIL in the type 1 diabetes mouse
model induced by multiple low doses of STZ.
RESEARCH DESIGN AND METHODS
Cell cultures. Human and mouse peripheral blood was obtained from ﬁve
independent healthy blood donors and four C57 black mice, respectively.
Human and mouse mononuclear cells (PBMCs) were isolated by density
gradient (Ficoll/Histopaque-1077; Sigma, St. Louis, MO; or Lympholyte-M;
Cederlane Laboratories, Hornby, ON, Canada, respectively) and cultured in
RPMI-1640 containing 10% FBS (Gibco BRL, Grand Island, NY).
Human islets were obtained from the European Consortium for islet
transplantation (ECIT) for the research distribution program (Human Islet
Isolation Facility, San Raffaele Institute, Milano, Italy). Islet preparations, with
purity 70%, not suitable for transplantation, were obtained and cultured in
CMRL medium-1066 (Invitrogen, Carlsbad, CA) with 10% FBS, as previously
described (11).
Cell cultures were treated with recombinant TRAIL (1 g/ml), prepared as
described (12), for 72 h. Cell viability was monitored over time by Trypan blue
dye exclusion, and apoptosis was monitored by double staining with Annexin
V/propidium iodide, as previously described (13).
RNA and protein analyses. Validation of array results and investigation of
speciﬁc gene expression were carried out in RNA samples with the real-time
thermal analyzer Rotor-Gene 6000 (Corbett, Cambridge U.K.), by using SYBR
Green–based technology and the RT-PCR primer set for human SOCS1 cDNA
(SABioscience, Frederick, MD) or mouse SOCS1 and vascular cell adhesion
molecule (VCAM)-1 cDNAs (Qiagen, Hilden, Germany). Gene expression of
the target sequences was normalized in relation to the expression of endog-
enous controls. Each sample was tested in triplicate. (See also the online
appendix, available at http://diabetes.diabetesjournals.org/cgi/content/full/
db09-1771/DC1.)
For Western blot analyses, PBMC samples were lysed as previously
described (14). Equal amounts of protein for each sample were migrated in
acrylamide gels and blotted onto nitrocellulose ﬁlters. The following antibod-
ies were used: monoclonal antibody anti-SOCS1 and anti-tubulin (purchased
from Santa Cruz Biotechnology, Santa Cruz, CA, and Sigma, respectively).
After incubation with peroxidase-conjugated anti-mouse IgG, speciﬁc reac-
tions were revealed with the ECL detection kit (Amersham Pharmacia
Biotech, Piscataway, NJ). Densitometry values were estimated by the Image-
Quant TL software (Amersham).
Animal studies. Animal care and treatments were conducted in conformity
with institutional guidelines in compliance with national and international
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6-week-old C57 black mice were rendered diabetic by ﬁve daily intraperitoneal
injections of STZ (Sigma) at a dose of 50 mg/kg. Half of the mice treated with
STZ (n  12) were also co-injected daily with recombinant TRAIL (20 g/day)
(12). Control mice received the vehicle citrate buffer alone (mock treated; n 
10). An additional group of nondiabetic mice (n  10) was treated with
recombinant TRAIL (20 g/day) for 5 consecutive days.
The animals had unrestricted access to water and were maintained on a
12-h light-dark cycle in a non–pathogen-free environment on standard mouse
food (Harlan Nossan Correzzana, Milan, Italy). Serum glucose concentrations
were determined weekly by an autoanalyzer technique (Hitachi 717; Tokyo,
Japan). After 6 weeks, the animals were anesthetized by an intraperitoneal
injection of pentobarbital sodium (60 mg/kg) and killed for blood harvesting
and histological examination of pancreas. Blood was immediately centrifuged
to remove cells, and serum was collected for enzyme-linked immunosorbent
assay (ELISA) assays. Insulin, TNF-, and osteoprotegerin (OPG) were
measured in serum samples using the insulin mouse ultrasensitive ELISA kit
(DRG Instruments, Marburg, Germany) and the mouse TNF- and OPG ELISA
kits (both purchased from R&D System, Minneapolis, MN), according to the
manufacturer’s instructions. Measurements were performed in duplicates.
Pancreas samples were frozen for RNA extraction and were embedded in
parafﬁn for histological examination. The distribution and morphology of
pancreatic islets were assessed by analyzing 4-m-thick cross-sectional serial
sections after staining with hematoxylin and eosin. Pancreatic islets were
manually traced on the computer, and area measurements were performed,
using a video-based image analysis program (MCID; Imaging Research, St.
Catharine’s, ON, Canada).
Statistical analysis. Data were calculated and shown as mean  SD or as
median and interquartile range (IQR), according to the distribution. Compar-
isons between STZ-treated animals and normal controls were performed with
Student t test and with 
2 test. Differences in parameters mean values across
study phases were analyzed using ANOVA for repeated measures. Statistical
signiﬁcance was deﬁned as P  0.05.
RESULTS
In vitro treatment with recombinant TRAIL upregu-
lates the expression of SOCS1 in PBMCs and human
islets. Starting from preliminary cDNA microarray analy-
ses of human PBMC cultures exposed to recombinant
TRAIL, which identiﬁed SOCS1 as one of the most upregu-
lated genes in response to TRAIL, we validated this
observation by quantitative RT-PCR for SOCS1 in both
human PBMCs and mouse PBMCs (Fig. 1A). The signiﬁ-
cant upregulation of the steady-state mRNA levels of
SOCS1 was conﬁrmed at the protein level by analyzing
SOCS1 protein by Western blot (Fig. 1B). Because SOCS1
is known to downregulate the sensitivity of pancreatic
-cells to interferon-	 (IFN-	) and TNF- (7–9), the effect
of TRAIL was next analyzed in human pancreatic islets. In
vitro treatment with recombinant TRAIL upregulated
SOCS1 mRNA expression also in human islets (Fig. 1C).
In vivo injection of recombinant TRAIL ameliorates
the glycemic levels in diabetic mice. Having demon-
strated that recombinant TRAIL promotes the expression
of SOCS1 in cultured human and mouse PBMCs, as well as
in puriﬁed human islets, next experiments were carried
out to evaluate the in vivo effect of TRAIL in a relevant
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FIG. 1. Effect of TRAIL on SOCS1 expression levels in vitro. PBMCs and pancreatic islet cultures were either left untreated or exposed to
recombinant TRAIL. Levels of SOCS1 mRNA and protein were analyzed by quantitative RT-PCR (A and C) and Western blot (B) analyses,
respectively. In A and C, after normalization to the level of the housekeeping genes, results were expressed as fold of SOCS1 mRNA induction
in TRAIL-treated cultures with respect to the control untreated cultures. Data are reported as means  SD of experiments, each performed in
triplicate. In B, the levels of SOCS1 protein were assessed by Western blot analysis in cell lysates. Tubulin staining is shown as a loading control.
Representative examples of Western blot results obtained from two (PB #1 and PB #2) out of ﬁve independent human PBMC cultures are shown.
After densitometric analyses, results were expressed as fold of SOCS1 protein induction in TRAIL-treated cultures with respect to the control
untreated cultures. *P < 0.05 with respect to untreated cells.
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peritoneal daily injections of low-dose (50 mg/kg) STZ
were administered to 6-week-old mice (n  24) that were
monitored for 6 weeks, in comparison with a group of
vehicle-treated control mice (n  10) (Fig. 2A). Half of
STZ-injected mice (n  12) also received ﬁve intraperito-
neal daily injections of recombinant TRAIL (20 g/injec-
tion) (Fig. 2A). It should be noticed that injection of
recombinant TRAIL performed in a group of nondiabetic
mice (n  10), following the same schedule of diabetic
mice (20 g/injection per 5 days, Fig. 2A), did not affect
any of the parameters examined in this study (glycemia,
body weight, insulinemia). These animals were indistin-
guishable from vehicle-injected control mice and therefore
have been omitted from the ﬁgures.
Mice treated with STZ alone displayed a signiﬁcant
increase of blood glucose levels from week 2 onward (Fig.
2B; from 98  19 mg/dl at week 0, up to 600  15 mg/dl at
week 6). Mice co-injected with STZTRAIL showed sig-
niﬁcantly (P  0.05) lower blood glucose levels with
respect to the animals injected with STZ alone, although
the blood glucose levels of this group remained higher
than in controls (Fig. 2B). In addition, mice co-injected
with STZTRAIL gained signiﬁcantly (P  0.05) more
weight than animals treated with STZ alone, although the
body weight of this group of animals remained lower with
respect to mock-treated animals (Fig. 2C).
In vivo injection of recombinant TRAIL exhibits
anti-inﬂammatory activity and partially preserves
pancreatic islets in diabetic mice. At the end of the
experimental period (6 weeks), animals were killed for
blood harvesting, to be used for the determination of the
circulating levels of insulin, TNF-, and OPG and for
histopathological examination of the pancreas (Fig. 3).
While insulinemia was signiﬁcantly (P  0.05) higher in
mice co-injected with STZTRAIL with respect to mice
injected with STZ alone (Fig. 3A), the levels of the inﬂam-
matory markers TNF- and OPG (8,9,15–17) were lower
(P  0.05) in SZTTRAIL-injected animals (Fig. 3B).
Because repeated injections of recombinant TRAIL atten-
uated hyperglycemia and increased insulinemia in the
majority of diabetic mice, we next examined the total area
and the morphology of pancreatic islets. While STZ in-
duced a dramatic decrease in the number and size of
pancreatic islets (Fig. 3C), the total area of pancreatic
islets was signiﬁcant higher (P  0.05) in SZTTRAIL-
injected animals than in STZ-injected mice (Fig. 3D).
Because the data illustrated above suggested that TRAIL
treatment decreases systemic markers of inﬂammation
(TNF- and OPG), in the last group of experiments, we
have analyzed the expression of VCAM-1, a well-deﬁned
marker of insulitis (9), and SOCS1 at the pancreatic level.
In vivo treatment with recombinant TRAIL signiﬁcantly
decreased the mRNA steady-state levels of pancreatic
VCAM-1 (Fig. 4). On the other hand, similarly to what was
observed in vitro (Fig. 1), SOCS1 mRNA levels were higher
in the pancreas of animals treated with STZTRAIL than
in animals treated with STZ alone (Fig. 4).
DISCUSSION
In type 1 diabetes, pancreatic islet inﬂammation contrib-
utes to the progressive loss of insulin-producing -cells,
which eventually renders the patients, many of them
children or adolescents, insulin dependent for life (18). In
this respect, we have demonstrated for the ﬁrst time that
exogenous recombinant TRAIL, co-injected with STZ, sig-
niﬁcantly reduced the levels of islet damage with respect
to animals injected with STZ alone. Consistently with a
protective role of recombinant TRAIL, the levels of insu-
linemia were signiﬁcantly (P  0.05) higher in mice
co-injected with STZTRAIL, and STZTRAIL-treated an-
imals showed reduced levels of hyperglycemia throughout
the whole period of the study with respect to STZ-injected
animals. Moreover, in keeping with previous studies dem-
onstrating that TRAIL displays anti-inﬂammatory activities
in vitro (19,20), the in vivo injection of recombinant TRAIL
signiﬁcantly decreased inﬂammatory markers, both at the
systemic (TNF- and OPG) and pancreatic (VCAM-1)
levels.
The hypothesis that TRAIL might ameliorate STZ-in-
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FIG. 2. Effect of in vivo injection of recombinant TRAIL on body weight
and glycemia in diabetic mice. A: Schematic representation of the
treatment protocol for each mice group. B: Kinetics of blood glucose
levels, reported as fold of increase with respect to time 0, for each
group of mice. Results are reported as means. *P < 0.05 vs. STZ mice
(without TRAIL). C: Body weight variation at 6 weeks is reported as
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is consistent with another important ﬁnding of our study:
the ability of TRAIL to induce SOCS1 expression in both
PBMCs and pancreatic islets. Although we are aware that
we have not formally demonstrated the role of SOCS1 in
mediating the protective effect of recombinant TRAIL, it is
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role in controlling the magnitude and duration of several
cytokine signals, which have been involved in the patho-
genesis of DMT1, such as in particular TNF- and IFN-	
(10). Interestingly, we have also shown that recombinant
TRAIL might increase SOCS1 expression also at the pan-
creatic level. This is particularly remarkable, since increas-
ing SOCS1 expression in -cells has been shown to inhibit
TNF-induced Fas expression in vitro and prevent the
progression to diabetes in NOD mice (21–23), and the
overexpression of SOCS1 in islet grafts may inhibit or
block the apoptotic pathway and prolong graft survival
(22).
Taking into account that 1) proinﬂammatory cytokines,
such as TNF- and IFN-	, signiﬁcantly contribute to
initiate -cell apoptosis in islets; 2) treatment with recom-
binant TRAIL does not impair the viability of pancreatic
islets, even when overexpressed (6); and 3) pancreatic
islet transplantation is an important therapeutic option to
avoid the need for lifelong hormone injections in type 1
diabetes (24), our current data suggest that systemic
treatment with recombinant TRAIL, which is currently
under investigation in phase I/II clinical trials for the
treatment of several tumors and is usually well tolerated
(1), might be considered as a therapeutic option for the
treatment of type 1 diabetes. This treatment would be
either administered alone in the early onset of type 1
diabetes or in association with islet transplantation in the
late phase of type 1 diabetes to attenuate the inﬂammatory
and autoimmune response.
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